"L'hôpital Lyon-Sud dispose de services d’excellence, notamment dans les domaines de la cancérologie, de l’hématologie, de la nutrition, de la dermatologie ainsi que dans de multiples spécialités chirurgicales comme l’orthopédie et la chirurgie digestive. C’est un établissement de référence dans la prise en charge des urgences, des femmes enceintes et des patients âgés."

During the past decade, Service d'Hématologie - Centre Hospitalier Lyon-Sud conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 10 clinical trials were completed, i.e. on average, 111.1% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" #1 sponsor was "Lymphoma Study Association" with 14 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Genentech, Inc." with 3 trials sponsored, "Groupe Francophone des Myelodysplasies" with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" #1 collaborator was "Amgen" with 4 trials as a collaborator, "Janssen-Cilag International NV" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Australasian Leukaemia and Lymphoma Group" with 1 trials as a collaborator and "Celgene" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" are "Follicular Lymphoma" (4 trials), "Multiple Myeloma" (4 trials), "Myelodysplastic Syndromes" (4 trials), "Diffuse Large Cell Lymphoma" (3 trials) and "Chronic Lymphocytic Leukemia" (2 trials). Many other conditions were trialed in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" in a lesser frequency.

Most popular intervention types in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" are "Drug" (35 trials), "Procedure" (5 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (9 trials), "Prednisone" (6 trials), "Cyclophosphamide" (5 trials), "rituximab" (5 trials) and "Doxorubicin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Service d'Hématologie - Centre Hospitalier Lyon-Sud" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Service d'Hématologie - Centre Hospitalier Lyon-Sud". 1 are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Service d'Hématologie - Centre Hospitalier Lyon-Sud, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Service d'Hématologie - Centre Hospitalier Lyon-Sud, 8 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".